Basic Information
| LncRNA/CircRNA Name | MIR31HG |
| Synonyms | LncHIFCAR, hsa-lnc-31 |
| Region | GRCh38_9:21455642-21559669 |
| Ensemble | ENSG00000171889 |
| Refseq | NR_027054 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | head and neck cancer |
| ICD-0-3 | C76.0 |
| Methods | qPCR, Western blot, other |
| Sample | LSCC tissues |
| Expression Pattern | up-regulated |
| Function Description | MIR31HG overexpression or co-expression of HIF1A-positive and p21-negative could serve as a poor prognostic factor for LSCC patients. We further confirmed that MIR31HG promoted cell proliferation, cell cycle progression, and inhibited cell apoptosis in vitro and in vivo. The ingenuity pathway analysis and Western blot indicated that MIR31HG regulated cell cycle progression via HIF1A and p21 in HNSCC. The current results provide evidences for the role of MIR31HG in promoting HNSCC progression and identify MIR31HG as a prognostic biomarker and putative therapeutic target in HNSCC. |
| Pubmed ID | 30458787 |
| Year | 2018 |
| Title | LncRNA MIR31HG targets HIF1A and P21 to facilitate head and neck cancer cell proliferation and tumorigenesis by promoting cell-cycle progression. |
External Links
| Links for MIR31HG | GenBank HGNC NONCODE |
| Links for head and neck cancer | OMIM COSMIC |